EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study

Govind Kallee iD, Gérard Milano, Florence Duffaud, Laetitia Dahan, Joseph Ciccolini iD

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Govind Kallee und 4 weiteren Autor:innen. Beteiligte Einrichtung: PRISM, Biogenopôle La Timone University Hospital of Marseille, Marseille, France. Hauptthemen laut MEDLINE: Fluorouracil, Dihydrouracil Dehydrogenase (NADP), Antimetabolites, Antineoplastic, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anticancer drug 5FU is extensively metabolized by dihydropyrimidine dehydrogenase (DPD), an enzyme with high interindividual variability. Poor metabolizer (PM, i.e., DPD deficient) patients are at risk of life‐threatening toxicities. Whether ultra‐rapid metabolizer (UM) status could conversely compromise 5FU efficacy remains to be investigated.

Methods

In this real‐world study, 352 adult patients treated with a 5FU‐containing regimen were screened. Patients were classified as normal (extensive metabolizer, EM), PM, or UM on DPD function based upon baseline plasma uracil monitoring. The impact of DPD status on efficacy and safety endpoints was investigated.

Results

Patients were categorized on DPD as UM (11.9%), EM (75.9%), and PM (12.2%). The response rate was 54.5%, with median PFS and OS of 13.9 and 19 months, respectively. PM patients were treated with an average 13% lower 5FU starting dose. There was no statistical difference in efficacy between UM and other patients. Severe toxicities were observed in less than 5% of patients, an incidence significantly lower than commonly reported with 5FU‐containing regimen and was comparable between UM, EM, and PM patients. Our observations suggest that UM status is not associated with the lack of efficacy of 5FU. In addition, upfront DPD testing with adaptive dosing helps to reduce the incidence of severe toxicities, as PM patients on reduced doses did not have more severe toxicities than other patients treated with standard doses, while exhibiting similar efficacy in terms of response rate and survival.

Conclusion

When upfront DPD screening with adaptive dosing is performed, no difference is observed between UM, EM, and PM patients in terms of efficacy and safety. Trial Registration #PADSA3GKW7

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluorouracilDihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticNeoplasmsDihydropyrimidine Dehydrogenase DeficiencyHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

5FUDPDefficacysafety

Substanzen

FluorouracilDihydrouracil Dehydrogenase (NADP)Antimetabolites, Antineoplastic

Autor:innen und Institutionen

  • PRISM, Biogenopôle La Timone University Hospital of Marseille, Marseille, France.
  • COMPO, Inserm U1068 CRCM, Marseille, France.
  • Centre Antoine Lacassagne, Nice, France.
  • Medical Oncology, La Timone University Hospital of Marseille, Marseille, France.
  • Digestive Oncology, La Timone University Hospital of Marseille, Marseille, France.

ORCID-Profile: Govind Kallee, Joseph Ciccolini

Zitieren

APA

Kallee, G., Milano, G., Duffaud, F., Dahan, L., & Ciccolini, J. (2025). DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70035

Vancouver

Kallee G, Milano G, Duffaud F, Dahan L, Ciccolini J. DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70035

BibTeX
@article{Kallee2025,
  author = {Kallee, Govind and Milano, Gérard and Duffaud, Florence and Dahan, Laetitia and Ciccolini, Joseph},
  title = {DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.70035}
}
Kostenlos starten →